SentreHEART
- Company typePublic
- Founded2005
- HeadquartersRedwood City, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
SentreHEART firmographics
Firmographics- Name
- SentreHEART
- Legal name
- AtriCure, Inc.
- Website
- https://sentreheart.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
SentreHEART industry classification
Industry- Product category
- Cardiac Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH)
- akta.pro secondary industry
- Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips) (HLAHALAD)
Keywords
Where SentreHEART is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Markets served
SentreHEART business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Distribution channels1 record
Marketing channels6 records
SentreHEART product offering
Product offeringCore offering
SentreHEART is a medical device company developing tissue closure solutions that give physicians control over remotely delivered sutures. The company focuses on cardiac intervention devices, including hybrid atrial fibrillation therapy devices, epicardial access instruments, and left atrial appendage management products used during cardiac surgery and electrophysiology procedures.
Product overview
AtriCure offers a comprehensive portfolio of medical devices for cardiac surgery focused on two main therapy areas: atrial fibrillation (AFib) treatment and post-operative pain management. The product portfolio includes ablation systems (radiofrequency and cryoablation), left atrial appendage management devices (AtriClip family), and cryo nerve block probes for pain management. Key product lines include the Isolator Synergy ablation clamps and pens, cryoICE cryoablation systems, the EPi-Sense device for Hybrid AF Therapy, and the full AtriClip device family for left atrial appendage exclusion. The company also provides minimally invasive surgical instruments and a Multifunctional Ablation Generator (MAG). The portfolio is organized around therapy platforms: Concomitant Surgical Ablation, Hybrid AF Therapy, Hybrid Total Thoracoscopic Therapy, Cryo Nerve Block Therapy, and Left Atrial Appendage Management (LAAM).
Differentiator
Problem solved
Functional benefit
Brands
- cryoICE: Cryoablation probes for surgical procedures
- cryoSPHERE
- AtriClip
- Isolator
- EPi-Sense
- Hybrid AF Therapy
- cryoFORM
- cryoXT
Products and services
- EPi-Sense Device
Companies that use SentreHEART
Customer profileSegments1 record
Ideal customer profiles1 record
SentreHEART technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
SentreHEART partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights2 records
SentreHEART competitors and assessment
Company assessmentOthers
- Stereotaxis: Robotic magnetic navigation system provider for cardiac ablation procedures, supplying enabling technology to electrophysiology labs where SentreHEART's closure devices may be deployed.
Emerging players
- Occlutech: Specialist structural heart occlusion company developing LAA and other cardiac closure devices, providing a direct emerging competitor in the same closure-device category as SentreHEART.
- Conformal Medical: Private LAA closure developer (CLAAS system) competing in the same left-atrial appendage closure space as SentreHEART with a next-generation conformable device design.
- Cardia (cardiacDimensions): Structural heart company developing implant-based devices for cardiovascular applications; a comparable small-stage developer with niche mechanical solutions addressing cardiac procedural needs.
Broad incumbents
- Medtronic: World-leading cardiovascular device company with electrophysiology, surgical ablation, and cardiac rhythm management businesses directly adjacent to SentreHEART's procedural domain.
- Boston Scientific: Large-cap medical device company whose Watchman is the market-leading endocardial LAA closure device, addressing the same stroke-prevention unmet need served by SentreHEART's closure technology.
- Johnson & Johnson (Biosense Webster): Biosense Webster is the dominant electrophysiology franchise globally; competes in ablation and LAA management pipelines that overlap with SentreHEART's target procedures.
- AtriCure: NASDAQ-listed atrial fibrillation and pain management medical device company; competes directly in LAA exclusion (AtriClip) and surgical ablation and is the only natural strategic acquirer given its overlap with SentreHEART's tissue-closure focus.
- Abbott: Global medical device incumbent with a structural heart and electrophysiology portfolio (including Amplatzer and EP catheters) that competes with cardiac surgery and LAA management markets.
Regional players
- Lifetech Scientific: China-based cardiovascular and structural heart device company with an LAA occluder line (LAmbre) covering the same clinical indication served by SentreHEART, primarily in the Asia-Pacific market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key highlights5 records
Customer concentration
SentreHEART social profiles
Digital presenceSentreHEART financial estimates
Financial estimateRevenue estimate
Valuation estimate
SentreHEART leadership team
Management profileNumber of profiles
Profiles1 record
SentreHEART subsidiaries and ownership
Company hierarchySubsidiaries3 records
SentreHEART funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SentreHEART M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SentreHEART
What does SentreHEART do?
SentreHEART is a medical device company developing tissue closure solutions that give physicians control over remotely delivered sutures. The company focuses on cardiac intervention devices, including hybrid atrial fibrillation therapy devices, epicardial access instruments, and left atrial appendage management products used during cardiac surgery and electrophysiology procedures.
Is SentreHEART a public or private company?
SentreHEART is a public company. It is classified as venture growth investor backed and is currently operating.
When was SentreHEART founded?
SentreHEART was founded in 2005. It employs 51 to 100 people.
Where is SentreHEART based?
SentreHEART is headquartered in Redwood City, United States, in the North America region.
Who are SentreHEART's main competitors?
Stereotaxis is listed as an others. Emerging players are Occlutech, Conformal Medical and Cardia (cardiacDimensions). Broad incumbents are Medtronic, Boston Scientific, Johnson & Johnson (Biosense Webster), AtriCure and Abbott. Lifetech Scientific is listed as a regional player.
Does SentreHEART have an API?
No public API is recorded for SentreHEART.
What industry is SentreHEART in?
SentreHEART's product category is Cardiac Medical Devices. Its primary akta.pro industry code is HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts), with a secondary code of HLAHALAD, Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips). Its NAICS code is 334510 and its SIC code is 3841.